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Specific point mutations in caveolin-3, a predomi-
nantly muscle-specific member of the caveolin family,
have been implicated in limb-girdle muscular dystrophy
and in rippling muscle disease. We examined the effect
of these mutations on caveolin-3 localization and func-
tion. Using two independent assay systems, Raf activa-
tion in fibroblasts and neurite extension in PC12 cells,
we show that one of the caveolin-3 point mutants, caveo-
lin-3-C71W, specifically inhibits signaling by activated
H-Ras but not by K-Ras. To gain insights into the effect
of the mutant protein on H-Ras signaling, we examined
the localization of the mutant proteins in fibroblastic
cells and in differentiating myotubes. Unlike the previ-
ously characterized caveolin-3-DGV mutant, the inhibi-
tory caveolin-3-C71W mutant reached the plasma mem-
brane and colocalized with wild type caveolins. In BHK
cells, caveolin-3-C71W associated with caveolae and in
differentiating muscle cells with the developing T-tu-
bule system. In contrast, the caveolin-3-P104L mutant
accumulated in the Golgi complex and had no effect on
H-Ras-mediated Raf activation. Inhibition by caveolin-
3-C71W was rescued by cholesterol addition, suggesting
that the mutant protein perturbs cholesterol-rich raft
domains. Thus, we have demonstrated that a naturally
occurring caveolin-3 mutation can inhibit signaling in-
volving cholesterol-sensitive raft domains.
Caveolae are an abundant feature of the sarcolemma of
muscle cells. Caveolin-3 (Cav3)1 is one of the major membrane
proteins of skeletal and cardiac muscle caveolae (1, 2). By
analogy to the closely related caveolin family member, caveo-
lin-1 (Cav1) (3), Cav3 is thought to play a vital and direct role
in the formation of the characteristic flask-shaped pits typical
of caveolae. In addition to this structural role, caveolins have
been implicated in signal transduction and in lipid transport
(4). The role of caveolae and Cav3 in muscle has become clini-
cally relevant with the finding that mutations in the gene for
Cav3 are associated with several muscle pathologies including
a rare form of limb-girdle muscular dystrophy type 1C and
hereditary rippling muscle disease (5–10). To date, one mi-
crodeletion and five point mutations (R26Q, A45T or A45V,
G55S, C71W, and P104L; note that this nomenclature assumes
a single Met at the N terminus) have been described. While
four of these mutant proteins cause a decrease in Cav3 expres-
sion, in other cases surface expression of the protein appears
normal (5, 6). Defining the function of Cav3, identifying its
interacting partners, and characterizing the effect of the my-
opathy-associated mutations on muscle function is therefore of
vital importance. Moreover, the specific point mutants of Cav3
that are associated with the skeletal muscle defects may pro-
vide powerful new tools in studies of the role of caveolins in
both muscle and nonmuscle cells.
Cav3 expression is up-regulated as myoblasts fuse to form
myotubes (1, 2, 11). In mature muscle, the sarcolemma is
highly organized into regularly spaced Cav3-positive caveolar
domains separated by noncaveolar domains (12). Cav3 shows
partial colocalization with elements of the dystrophin complex
(12) and is proposed to associate with the dystrophin complex
at the cell surface (13, 14). In fact, interactions between Cav3
and dystroglycan through a WW-like domain in Cav3 have
been suggested to mediate a direct interaction between these
two proteins (15). While Cav3 is predominantly associated with
the sarcolemma of mature muscle, in differentiating muscle
cells Cav3 associates with the developing T-tubule system (11,
16). The functional significance of the association with this
extensive plasma membrane subdomain is as yet unknown, but
both caveolae and the developing T-tubule system show similar
morphology and are sensitive to cholesterol-disrupting agents
(11, 17, 18). Recent reports of T-tubule defects in Cav3-deficient
mice suggest that Cav3 may be involved in the organization of
the T-tubules but is not essential for their formation (19).
Caveolins have been shown to interact in vitro with a num-
ber of signaling molecules including trimeric G protein sub-
units, Src kinases, and Raf through direct interactions of these
proteins with a conserved region of caveolin termed the caveo-
lin scaffolding domain (20). More recent studies have shown
that this domain of caveolin can interact with, and apparently
insert into, lipid bilayers (21, 22) raising questions regarding
the specificity of these protein-protein interactions in vivo. An
additional hypothesis for the role of caveolins has emerged with
the finding that Cav1 is a lipid-binding protein. Cav1 binds
both cholesterol (23) and fatty acids (24), and its expression is
regulated by cholesterol at the transcriptional level (25–27).
Cav1 expression also increases cholesterol transport (28). Con-
sistent with these findings, we have shown that exogenous
* This research was supported by grants from the National Health
and Medical Research Council of Australia (to R. G. P. and J. F. H.).
The Centre for Functional and Applied Genomics is a Special Research
Centre of the Australian Research Council. The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ Both authors contributed equally to this work.
¶ Also supported by the Royal Children’s Hospital Foundation,
Queensland.
 To whom correspondence should be addressed. Tel.: 61-7-3365-6468;
Fax: 61-7-3365-4422; E-mail: R.Parton@imb.uq.edu.au.
1 The abbreviations used are: Cav, caveolin; HA, hemagglutinin; WT,
wild type; MEK, mitogen-activated protein kinase/extracellular signal-
regulated kinase kinase; ERK, extracellular signal-regulated kinase;
YFP, yellow fluorescent protein; GFP, green fluorescent protein; MES,
4-morpholineethanesulfonic acid.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 20, Issue of May 17, pp. 17944–17949, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org17944









expression of a Cav3 truncation mutant, Cav3-DGV, in fibro-
blastic cells disrupts lipid transport and causes inhibition of
specific signaling pathways (29). Rather than a direct interac-
tion with signaling proteins, these studies suggest that the
mutant protein affects lipid homeostasis and so causes disrup-
tion of cholesterol-rich surface domains, termed lipid rafts,
with which specific signaling pathways are associated (4). The
muscle cell surface has been shown to be arranged into highly
organized arrays of caveolae raft domains (12). In view of the
finding that artificial Cav3 truncation mutants can inhibit
signal transduction through raft domains (29), we speculated
that naturally occurring Cav3 mutants may also affect signal-
ing through sarcolemmal raft domains and that these mutants
may provide excellent tools to dissect caveolin function. In the
present study, we have characterized the mutant Cav3 proteins
functionally using two different assays to monitor raft- and
non-raft-mediated Ras-dependent signaling events. We show
that one Cav3 point mutant reaches the cell surface and spe-
cifically inhibits H-Ras-dependent signaling pathways with the
inhibition being rescued by cholesterol addition. These findings
give new insights into the effect of specific point mutations on
caveolin function, the role of caveolins in regulating raft-de-
pendent signaling events, and the potential effect of caveolin
dysfunction in muscle.
MATERIALS AND METHODS
Cell Culture—BHK cells and C2C12 cells were maintained as de-
scribed previously (17, 29). PC12 cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 5% (v/v) horse serum, 10%
(v/v) fetal calf serum, and 2 mM L-glutamine.
Antibodies and cDNAs—Affinity-purified rabbit antibodies against
p23 (30) were kindly provided by Professor Jean Gruenberg (University
of Geneva, Switzerland). A rabbit polyclonal antibody against the he-
magglutinin (HA) tag was a generous gift from Professor David James
(University of Queensland, Australia). A rabbit polyclonal antibody to
the conserved region of Cav3 (Con-Cav) has been characterized previ-
ously (32). A polyclonal antibody to Cav1 was from Transduction Lab-
oratories (catalog no. C13630). Other reagents have been described
previously (31). HA-tagged Cav3 point mutants were generated by PCR
using mouse HA-tagged Cav3 as template. Cav3-DGV has been de-
scribed previously (32). Cav3-LLS comprises residues 74–150 of Cav3.
All constructs were confirmed by sequencing.
Transfections—BHK cells were transiently transfected using Lipo-
fectAMINE or LipofectAMINE Plus reagent (Invitrogen) according to
the manufacturer’s instructions. C2C12 cells were transiently trans-
fected using LipofectAMINE 2000 reagent (Invitrogen) according to the
manufacturer’s instructions. Briefly, myoblasts were transfected at con-
fluence in differentiation medium (Dulbecco’s modified Eagle’s medium
with 1% (v/v) Serum Supreme (BioWhittaker) and 2 mM L-glutamine)
using 4 g of total DNA/14 l of LipofectAMINE 2000 in a total volume
of 2.4 ml of medium (Invitrogen). Cells were incubated overnight with
the DNA mixture before it was replaced by fresh differentiation me-
dium, which was subsequently replaced every 2 days prior to fixation,
which routinely occurred 4–6 days postremoval of the transfection
reagent (at which point the myoblasts had morphologically fused to
form multinucleated myotubes). PC12 cells were transiently trans-
fected using LipofectAMINE according to the manufacturer’s instruc-
tions. Cells were left with the DNA transfection mix for 5 h prior to
addition of medium containing 20% (v/v) calf serum. This medium was
replaced the following day by standard PC12 maintenance medium, and
the cells were incubated a further 24 h prior to fixation. In BHK cells,
the HA-tagged wild type (WT) and mutant Cav3 proteins were ex-
pressed at comparable levels. Note that no correlation was found be-
tween expression level of the HA-tagged proteins and ability of the
mutants to inhibit H-Ras function.
Raf-1 Kinase Assays—Membrane fractions (P100) from transfected
BHK cells were normalized for Raf protein content via Western blot
analysis and assayed for Raf activity using a two-stage coupled MEK/
ERK assay with phosphorylation of myelin basic protein as readout
exactly as described previously (33). Cholesterol supplementation was
carried out for 1 h using a mix of 16 g/ml cholesterol with 0.4%
cyclodextrin in Dulbecco’s modified Eagle’s medium exactly as de-
scribed previously (34).
Sucrose Gradients and Western Blots—Sucrose gradients of trans-
fected BHK cells and subsequent Western blot analysis were performed
exactly as described previously (31, 35, 36).
Light and Electron Microscopy—For immunofluorescence studies,
cells were routinely fixed with 4% paraformaldehyde and immunola-
beled according to Pol et al. (37). Electron microscopic localization of
Cav3 mutants in plasma membrane sheets was performed exactly as
described previously (31).
RESULTS AND DISCUSSION
A Caveolin-3 Point Mutant Specifically Inhibits H-Ras-me-
diated Signaling—We used a model fibroblast transfection sys-
tem to examine the possible effect of Cav3 myopathy mutants
on H- or K-Ras-mediated Raf activation. Ras recruits Raf from
the cytosol to the plasma membrane where Raf activation pro-
ceeds through a complex pathway involving interactions with
lipids, displacement of 14-3-3, and phosphorylation (38). By
co-expression of the mutants with activated Ras (H- or K-Ras)
and with Raf, we examined the effect of the Cav3 mutants on
two aspects of Ras function: association of Raf with membranes
(Raf recruitment) and activation of Raf (Raf specific activity). It
was found that, as has been published previously (29), neither
Ras expression nor recruitment of Raf to the membrane by
constitutively activated H-Ras (H-RasG12V) or K-Ras (K-
RasG12V) was affected by co-expression of the mutant proteins
(data not shown). Moreover, Raf activation by K-Ras was also
unaffected by co-expression of the WT or mutant Cav3 proteins
(Fig. 1). In striking contrast, one of the mutants, Cav3-C71W,
showed a strong inhibition of H-Ras-mediated Raf activation.
The level of inhibition was comparable to that seen with the
previously documented Cav3-DGV N-terminal truncation mu-
tant (which lacks amino acids 1–54) (29) (Fig. 1). Cav3-WT and
the Cav3-G55S and Cav3-P104L mutants had no significant
effect on H-Ras-mediated Raf activation. Since the caveolin
scaffolding domain (amino acids 55–73), in which three dystro-
phy-associated mutations occur, has been implicated in the
direct binding of signaling molecules, we also examined
whether a caveolin truncation mutant that lacks this region
would inhibit H-Ras-mediated Raf activation as effectively as
the Cav3-DGV mutant. In fact, the Cav3-LLS mutant, which
lacks the entire N-terminal domain of Cav3 (amino acids 1–73),
was a specific and potent inhibitor of H-Ras-mediated Raf
activation showing that the scaffolding domain was not re-
quired for the inhibitory effect.
To validate the use of the Ras/Raf transfection assay for
studies of the caveolin mutants, we examined whether the
Cav3-C71W mutant would inhibit signaling in a completely
different Ras assay system. For this we took advantage of the
well characterized role of Ras in regulating neurite outgrowth
in PC12 cells (39). Introduction of activated H-Ras (Fig. 2) or
K-Ras (not shown) into undifferentiated PC12 cells caused
extensive neurite outgrowth, although the extent of neurite
outgrowth induced by K-Ras was not as marked as that in-
duced by H-Ras. Activated H-Ras was then transfected into
PC12 cells together with Cav3-WT, Cav3-DGV, or the Cav3
point mutants. As shown in Fig. 2, Cav3-DGV and Cav3-C71W
caused a dramatic inhibition of H-Ras-mediated neurite exten-
sion. The same mutant proteins had no effect on K-Ras-medi-
ated neurite outgrowth (results not shown). Thus, we have
identified a point mutation in Cav3 that inhibits H-Ras signal-
ing in two independent assays.
Localization of Heterologously Expressed Caveolin-3 Mutants
in Fibroblasts and Differentiating Muscle Cells—We have pos-
tulated that Cav3-DGV specifically inhibits H-Ras signaling
through an effect on cellular cholesterol. Cav3-DGV accumu-
lates intracellularly and does not reach the cell surface. We
therefore examined the localization of the inhibitory and non-
inhibitory Cav3 point mutants in fibroblasts and in differenti-
ating muscle cells. Cav3-WT localizes to surface caveolae and
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the Golgi complex of nonmuscle cells (32) and to surface caveo-
lae and T-tubules of differentiating muscle cells (11). We there-
fore examined whether the Cav3 point mutants showed aber-
rant localization by expression of the HA epitope-tagged forms
of the protein in BHK cells. By immunofluorescence micros-
copy, the labeling patterns for Cav3-G55S and Cav3-C71W
were indistinguishable from Cav3-WT-HA. In contrast, Cav3-
P104L was predominantly (although not exclusively) in the
Golgi complex, consistent with previous studies (40). We then
examined the localization of the mutant proteins in C2C12 cells,
a model muscle cell line. As in the nonmuscle cells, the labeling
patterns for Cav3-G55S and -C71W were largely indistinguish-
able from Cav3-WT, labeling the cell surface and putative
T-tubules. The Cav3-P104L mutant, in contrast, gave a strik-
ing perinuclear labeling, which colocalized with the cis Golgi
marker protein, p23, in all the transfected cells (Fig. 3).
In view of the inhibitory effect of the Cav3-C71W mutant, we
examined the localization of this protein in more detail. By
confocal microscopy the Cav3-C71W mutant colocalized with
Cav3-WT-YFP in co-transfected C2C12 cells (Fig. 3). In BHK
cells, Cav3-C71W localized to caveolae as shown by immuno-
electron microscopy on plasma membrane sheets (Fig. 3).
FIG. 1. A caveolin-3 point mutant specifically inhibits H-Ras-
dependent Raf activation. BHK cells were transfected with the in-
dicated combinations of activated H- or K-Ras (G12V), Raf, and Cav3
mutant constructs. The cells were then fractionated, and 20 g of each
membrane (P100) fraction were immunoblotted for Ras and Raf-1. P100
fractions from H-Ras (A) and K-Ras transfection series (B) were then
normalized for Raf content and assayed for Raf specific activity using a
coupled MEK/ERK assay. The results show relative Raf specific activ-
ity  S.E. from three to five independent experiments for each bar.
Each assay set was normalized against the Raf activity of cells trans-
fected with Ras and Raf alone (1). C shows the relative expression
levels of two of the HA-tagged Cav3 constructs compared with that of
endogenous Cav1 in BHK cells. Extracts from BHK cells transfected
with Cav3-C71W or Cav3-P104L were processed for Western blot anal-
ysis and probed with antibodies to the HA tag (upper panel A) to detect
transfected proteins (T) with an antibody (Con-Cav) to the conserved
region of Cav3 (middle panel B) or with a polyclonal antibody (Cav1)
to Cav1 (bottom panel C). The Con-Cav and Cav1 antibodies recog-
nize both endogenous Cav1 (E) and ectopically expressed Cav3 (T) with
varying affinities. Densitometric analysis of blots obtained with the
Con-Cav antibody showed that, after correction for transfection effi-
ciency, Cav3-P104L levels were approximately 6-fold and Cav3-C71W
levels were approximately 3-fold greater than those of endogenous
Cav1.
FIG. 2. Specific inhibition of H-Ras-stimulated neurite out-
growth in PC12 cells by caveolin-3 mutants. PC12 cells were trans-
fected with the indicated constructs. After 48 h the cells were fixed and
examined by fluorescent microscopy. A, cells transfected with the con-
trol vector (GFP-tH) have no neurites, whereas cells transfected with
GFP-H-RasG12V show extensive neurite outgrowth. In cells coexpress-
ing H-RasG12V and Cav3-C71W or Cav3-DGV neurite outgrowth is
severely inhibited. Negligible effects on neurite outgrowths are seen
when H-RasG12V is co-expressed with Cav3-WT or Cav3-P28H/C71W.
B, cells co-transfected with GFP-H-RasG12V and the indicated HA-
tagged Cav3 mutants were labeled with antibodies to HA and imaged
for both constructs as shown. Unlike Cav3-C71W, Cav3-C71A had
no impact on H-RasG12V-induced neurite outgrowth. Bars, 25 m.
The experiments shown are representative of three independent
experiments.
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Therefore Cav3-C71W behaves in a manner similar to the
Cav3-DGV mutant in terms of its effect on H-Ras signaling but
does not localize to the same compartment; in fact the Cav3-
C71W mutant traffics in a manner similar to the wild type
protein. The results also show for the first time that the Cav3-
P104L mutant is strongly retained in the Golgi complex of
muscle cells, consistent with results in fibroblasts (40). The
results also show that accumulation of a caveolin mutant in-
tracellularly is not sufficient to inhibit H-Ras signaling, em-
phasizing the specificity of the inhibition mediated by the
Cav3-DGV mutant.
Inhibition by the Caveolin-3-C71W Mutant Is Reversed by
Cholesterol Addition and Accompanied by Changes in Density
of Raft Domains—In view of the different location of the inhib-
itory mutants Cav3-DGV and Cav3-C71W, we examined
whether the Cav3-C71W mutant was inhibiting H-Ras signal-
ing through an effect on cholesterol as demonstrated previously
for the Cav3-DGV mutant. A cyclodextrin/cholesterol mixture
was used to supplement the cholesterol content of the plasma
membrane of cells expressing Cav3-C71W or Cav3-DGV. Strik-
ingly a 1-h incubation with cyclodextrin/cholesterol completely
restored Raf activity in cells expressing Raf, H-Ras, and Cav3-
C71W (Fig. 4), a similar effect to that seen in cells expressing
the Cav3-DGV mutant. This suggests that the Cav3-C71W
mutant perturbs cholesterol-dependent surface signaling
events. We therefore investigated whether Cav3-C71W caused
gross changes in free cholesterol distribution. No significant
changes were observed by filipin staining (results not shown).
We also examined whether Cav3-C71W showed different de-
tergent insolubility characteristics or oligomerization proper-
ties as compared with expressed wild type Cav3. In both cases
the properties of the Cav3-C71W mutant were indistinguish-
able from the wild type protein (results not shown).
We next examined whether expression of the Cav3-C71W
mutant affected raft domains. We used a modified flotation
method in which carbonate-treated membranes are separated
on a linear sucrose gradient to separate raft and non-raft
domains (31). Cav3-WT, Cav3-C71W, or Cav3-DGV were trans-
fected with GFP-tH, a raft marker comprising the H-Ras min-
imal membrane-targeting domain attached to the C terminus
of GFP. Both Cav3-C71W and Cav3-DGV, but not Cav3-WT,
caused a significant shift of the raft marker GFP-tH to denser
fractions (Fig. 5) consistent with the postulated effect of these
proteins on plasma membrane raft domains. Interestingly,
however, it was noted that the extent of the shift was different
for the two mutants with the Cav3-C71W mutant causing a
more modest shift of a portion of the GFP-tH from its normal
position on the density gradient. It is assumed that the in-
crease in density of the GFP-tH-containing rafts is due to a
decrease in cholesterol in raft domains, consistent with rescue
of H-Ras inhibition by cholesterol addition. Note that there was
no difference in the density of fractions containing Cav3-WT
and Cav3-C71W on the gradients (Fig. 5), further supporting
the localization data (Fig. 3). The flotation of endogenous Cav1
was also unaffected by co-expression of Cav3-C71W (data not
shown), highlighting the significance of the reproducible shift
FIG. 3. Localization of caveolin-3 mutants in BHK cells and
C2C12 cells. HA-tagged caveolin mutants were transfected into BHK
cells (A–E) or C2C12 myotubes (F–J) as indicated: Cav3-WT (A and F),
Cav3-G55S (B and G), Cav3-C71W (C and H), Cav3-P104L (D and I),
Cav3-P28H/C71W (E and J). In both cell types note the similar staining
patterns with Cav3-WT and both Cav3-C71W and Cav3-G55S, which
contrasts with the perinuclear labeling of the Cav3-P104L mutant. K
and L show colocalization between Cav3-P104L (L) and the Golgi
marker p23 (K). M and N indicate labeling for the inhibitory mutant
Cav3-C71W (M) and Cav3-WT-YFP (N). O shows electron microscopic
localization of Cav3-C71W on plasma membrane sheets using anti-HA
antibodies followed by 10-nm protein A-gold. Bars: A–N, 10 m; O,
100 nm.
FIG. 4. Inhibition of H-Ras signaling by caveolin-3 mutants is
reversed by cholesterol addition. BHK cells were transfected with
Raf-1 and activated H-Ras (G12V) in combination with the caveolin
constructs indicated. They were then treated with a cyclodextrin/cho-
lesterol (CD/Chol) mixture for 1 h or left untreated as indicated. The
cells were then fractionated, and 20 g of each membrane (P100)
fraction were immunoblotted for Ras and Raf-1. P100 fractions were
then normalized for Raf content and assayed for Raf specific activity
using a coupled MEK/ERK assay as described in Fig. 1. The results
show relative Raf specific activity S.E. from three to five independent
experiments for each bar. Expression of ectopically expressed caveolin
constructs was verified by Western blotting (not shown).
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observed for GFP-tH and suggesting that caveolae domains are
not significantly affected by mutant expression.
Amino Acid Substitution at Position 71 or Reduced Plasma
Membrane Localization of Caveolin-3-C71W Ablates the Inhib-
itory Effects of the Mutant Protein—Finally we explored the
relevant features of the Cav3-C71W mutant that make it in-
hibitory to H-Ras function. We first generated a new HA-
tagged Cav3 mutant, Cav3-C71A, in which the amino acid at
position 71 was changed from a cysteine to an alanine. This
mutant was used to determine whether the impact of the mu-
tation in Cav3-C71W is due to the loss of the cysteine residue,
which is conserved within Cav3 from different species, or to the
presence of the substituted bulky hydrophobic tryptophan.
Cav3-C71A localized in BHK cells in a manner indistinguish-
able from that observed for the Cav3-WT or Cav3-C71W mu-
tant (data not shown). Unlike the Cav3-C71W mutant, how-
ever, the Cav3-C71A mutant was unable to inhibit H-Ras-
mediated Raf activation (Fig. 1) and did not inhibit activated
H-Ras-mediated neurite outgrowth in the PC12 assay (Fig. 2).
This would argue that it is the acquisition of the tryptophan at
position 71 that alters Cav3 function.
In addition we investigated whether plasma membrane lo-
calization was essential for the inhibition of H-Ras signaling by
Cav3-C71W. The N terminus of Cav3 has been shown to be
required for caveolar localization of Cav3 (32). Consistent with
this, we have found that the introduction of point mutants in
conserved amino acids in this region, such as the arginine at
position 26 (a naturally occurring dystrophy mutant) and the
highly conserved proline at position 28, resulted in the intra-
cellular retention of the resultant mutants in the C2C12 system
(data not shown). As shown in Fig. 3, introducing a proline to
histidine change in Cav3-C71W at position 28 caused the mu-
tant protein (Cav3-P28H/C71W) to accumulate intracellularly
in BHK and C2C12 cells. The mutant protein was unable to
inhibit H-Ras-mediated Raf activation (Fig. 1). The lack of
inhibitory effect of the double mutant was confirmed using the
PC12 neurite outgrowth assay (Fig. 2).
We have shown, therefore, that a single point mutation in
Cav3, a cysteine to tryptophan substitution at amino acid po-
sition 71, can cause perturbation of cholesterol-dependent raft
signaling domains using two independent Ras assays. The Ras
assays provide powerful model systems to study raft-dependent
and -independent signaling pathways as shown in this and
previous studies (29, 31). Ras has been implicated in regulation
of muscle genes during differentiation and in response to nerve
activity, but the involvement of distinct Ras isoforms in muscle
is unknown. Genetic ablation of H-Ras (and N-Ras) expression
in mice had no discernible phenotype (41) in contrast to the
embryonically lethal effects of K-Ras ablation (42), suggesting
that H-Ras is not essential for muscle differentiation in vivo.
While we have used Ras as an assay, it is likely that other
signaling events utilizing raft domains may be affected in mus-
cle cells expressing the Cav3-C71W protein in vivo. A possibly
analogous situation was reported recently in neurons from
mice with Niemann-Pick type C in which it was shown that the
cholesterol imbalance associated with the disease caused de-
fects in specific raft-dependent signaling pathways (43). Inter-
estingly it has been reported that in Cav3 knockout mice the
dystrophin complex no longer floats on a sucrose density gra-
dient (19) implying that Cav3, via an ability to profoundly
influence raft domain formation, may also impact on the per-
formance of raft resident structural proteins.
We speculate that the Cav3-C71W-induced disruption of cho-
lesterol-rich domains in muscle may underlie the mild dystro-
phic phenotype caused by the mutant protein. However, it is
important to note that a recent study suggested that a number
of the described Cav3 point mutations also occurred in nondys-
trophic individuals and may therefore represent polymor-
phisms (44). In the case of Cav3-C71W, of 100 apparently
healthy individuals screened, one subject was found to carry
that mutation. In view of the striking effects of the mutant
protein described here, it is possible that the effects of Cav3-
C71W may be balanced by compensatory mechanisms in some,
but not all, genetic backgrounds. In support of this, it has
recently been reported that the Cav3-P104L mutation, origi-
nally documented in patients with limb-girdle muscular dys-
trophy, is also found in patients with a separate muscle disor-
der known as hereditary rippling muscle disease (10), further
verifying that both genetic and environmental backgrounds
influence phenotypic outcome.
The effects of the Cav3-C71W mutant show similarities to
those previously described for the Cav3-DGV mutant in the
specificity for H-Ras-mediated signaling events, rescue by ad-
dition of cholesterol, and the effect on the density of raft-
containing membranes (Ref. 29 and this study). However, un-
like the Cav3-DGV mutant, Cav3-C71W reaches cell surface
caveolae, and based on comparison with a double mutant im-
FIG. 5. Caveolin-3 mutants increase density of raft-contain-
ing membranes. BHK cells were transfected with GFP-tH alone or
in combination with Cav3-WT, Cav3-C71W, or Cav3-DGV as indi-
cated. Whole cell lysates prepared in 45% sucrose, 250 mM Na2CO3
were centrifuged under a sucrose gradient. Each fraction, numbered
from the top of the gradient, was then collected, diluted into MES-
buffered saline, pelleted, and immunoblotted. A, expression of Cav3-
C71W and Cav3-DGV alters the distribution of GFP-tH, whereas
expression of Cav3-WT does not. The lower two profiles show blotting
for HA-tagged Cav3-WT or Cav3-C71W in the same gradients. Cav3
shows an identical distribution to Cav3-C71W in the sucrose gradi-
ent. B, the top three immunoblots of A were then quantified by
phosphorimaging. These experiments show that Cav3-DGV and
Cav3-C71W expression cause a significant increase in the density of
GFP-tH-containing microdomains. Similar results were obtained in
three independent experiments.
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paired in transport to the surface, this surface localization may
be required for its inhibitory effects. Caveolins have been im-
plicated in cholesterol transport to the plasma membrane and
may therefore be important in regulating the availability of
plasma membrane cholesterol for raft domains. We have spec-
ulated that Cav3-DGV perturbs the distribution of free choles-
terol in the cell, causing intracellular accumulation in late
endosomes, and therefore reduces the availability of cholesterol
required for functional surface raft domains (37). As the Cav3-
C71W mutant has a similar effect and yet reaches the cell
surface and has no apparent gross effects on free cholesterol
distribution, the mechanisms involved are presumably distinct.
It is possible that the C71W mutation increases the affinity of
Cav3 for cholesterol and prevents release of cholesterol from
caveolae to noncaveolar lipid rafts, but further work is required
to test this hypothesis. Our results suggest that the addition of
tryptophan rather than the loss of cysteine may be important.
Interestingly the corresponding amino acid is highly conserved
in mammalian Cav1 and is a phenylalanine. Thus, the trypto-
phan substitution might make Cav3 more like Cav1 in this
region.
The identification of a single amino acid residue that changes
the properties of the Cav3 protein so dramatically provides a
valuable tool for studies of caveolins, cholesterol, and raft do-
mains. Moreover, we have revealed a potential mechanism by
which mutations in Cav3 can induce defects in specific signal-
ing pathways that could lead to long term pathological changes.
Acknowledgment—We are grateful to Rob Luetterforst for excellent
technical assistance.
REFERENCES
1. Way, M. & Parton, R. G. (1995) FEBS Lett. 376, 108–112
2. Tang, Z., Scherer, P. E., Okamoto, T., Song, K., Chu, C., Kohtz, D. S.,
Nishimoto, I., Lodish, H. F. & Lisanti, M. P. (1996) J. Biol. Chem. 271,
2255–2261
3. Fra, A. M., Williamson, E., Simons, K. & Parton, R. G. (1995) Proc. Natl. Acad.
Sci. U. S. A. 92, 8655–8659
4. Kurzchalia, T. V. & Parton, R. G. (1999) Curr. Opin. Cell Biol. 11, 424–431
5. McNally, E. M., de Sa Moreira, E., Duggan, D. J., Bonnemann, C. G., Lisanti,
M. P., Lidov, H. G., Vainzof, M., Passos-Bueno, M. R., Hoffman, E. P., Zatz,
M. & Kunkel, L. M. (1998) Hum. Mol. Genet. 7, 871–877
6. Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti,
E., Mazzocco, M., Egeo, A., Donati, M. A., Volonte, D., Galbiati, F., Cordone,
G., Bricarelli, F. D., Lisanti, M. P. & Zara, F. (1998) Nat. Genet. 18, 365–368
7. Carbone, I., Bruno, C., Sotgia, F., Bado, M., Broda, P., Masetti, E., Panella, A.,
Zara, F., Bricarelli, F. D., Cordone, G., Lisanti, M. P. & Minetti, C. (2000)
Neurology 54, 1373–1376
8. Herrmann, R., Straub, V., Blank, M., Kutzick, C., Franke, N., Jacob, E. N.,
Lenard, H. G., Kroger, S. & Voit, T. (2000) Hum. Mol. Genet. 9, 2335–2340
9. Sunada, Y., Ohi, H., Hase, A., Hosono, T., Arata, S., Higuchi, S., Matsumura,
K. & Shimizu, T. (2001) Hum. Mol. Genet. 10, 173–178
10. Betz, R. C., Schoser, B. G., Kasper, D., Ricker, K., Ramirez, A., Stein, V.,
Torbergsen, T., Lee, Y. A., Nothen, M. M., Wienker, T. F., Malin, J. P.,
Propping, P., Reis, A., Mortier, W., Jentsch, T. J., Vorgerd, M. & Kubisch,
C. (2001) Nat. Genet. 28, 218–219
11. Parton, R. G., Way, M., Zorzi, N. & Stang, E. (1997) J. Cell Biol. 136, 137–154
12. Rahkila, P., Takala, T. E., Parton, R. G. & Metsikko, K. (2001) Exp. Cell Res.
267, 61–72
13. Song, K. S., Scherer, P. E., Tang, Z., Okamoto, T., Li, S., Chafel, M., Chu, C.,
Kohtz, D. S. & Lisanti, M. P. (1996) J. Biol. Chem. 271, 15160–15165
14. Crosbie, R. H., Yamada, H., Venzke, D. P., Lisanti, M. P. & Campbell, K. P.
(1998) FEBS Lett. 427, 279–282
15. Sotgia, F., Lee, J. K., Das, K., Bedford, M., Petrucci, T. C., Macioce, P.,
Sargiacomo, M., Bricarelli, F. D., Minetti, C., Sudol, M. & Lisanti, M. P.
(2000) J. Biol. Chem. 275, 38048–38058
16. Ralston, E. & Ploug, T. (1999) Exp. Cell Res. 246, 510–515
17. Carozzi, A. J., Ikonen, E., Lindsay, M. R. & Parton, R. G. (2000) Traffic 1,
326–341
18. Ishikawa, H. (1968) J. Cell Biol. 38, 51–66
19. Galbiati, F., Engelman, J. A., Volonte, D., Zhang, X. L., Minetti, C., Li, M.,
Hou, H., Jr., Kneitz, B., Edelmann, W. & Lisanti, M. P. (2001) J. Biol.
Chem. 276, 21425–21433
20. Razani, B., Schlegel, A. & Lisanti, M. P. (2000) J. Cell Sci. 113, 2103–2109
21. Schlegel, A., Schwab, R. B., Scherer, P. E. & Lisanti, M. P. (1999) J. Biol.
Chem. 274, 22660–22667
22. Arbuzova, A., Wang, L., Wang, J., Hangyas-Mihalyne, G., Murray, D., Honig,
B. & McLaughlin, S. (2000) Biochemistry 39, 10330–10339
23. Murata, M., Peranen, J., Schreiner, R., Wieland, F., Kurzchalia, T. V. &
Simons, K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10339–10343
24. Trigatti, B. L., Anderson, R. G. & Gerber, G. E. (1999) Biochem. Biophys. Res.
Commun. 255, 34–39
25. Hailstones, D., Sleer, L. S., Parton, R. G. & Stanley, K. K. (1998) J. Lipid Res.
39, 369–379
26. Bist, A., Fielding, P. E. & Fielding, C. J. (1997) Proc. Natl. Acad. Sci. U. S. A.
94, 10693–10698
27. Fielding, C. J., Bist, A. & Fielding, P. E. (1997) Proc. Natl. Acad. Sci. U. S. A.
94, 3753–3758
28. Smart, E. J., Ying, Y., Donzell, W. C. & Anderson, R. G. (1996) J. Biol. Chem.
271, 29427–29435
29. Roy, S., Luetterforst, R., Harding, A., Apolloni, A., Etheridge, M., Stang, E.,
Rolls, B., Hancock, J. F. & Parton, R. G. (1999) Nat. Cell Biol. 1, 98–105
30. Rojo, M., Pepperkok, R., Emery, G., Kellner, R., Stang, E., Parton, R. G. &
Gruenberg, J. (1997) J. Cell Biol. 139, 1119–1135
31. Prior, I. A., Harding, A., Yan, J., Sluimer, J., Parton, R. G. & Hancock, J. F.
(2001) Nat. Cell Biol. 3, 368–375
32. Luetterforst, R., Stang, E., Zorzi, N., Carozzi, A., Way, M. & Parton, R. G.
(1999) J. Cell Biol. 145, 1443–1459
33. Roy, S., Lane, A., Yan, J., McPherson, R. & Hancock, J. F. (1997) J. Biol. Chem.
272, 20139–20145
34. Furuchi, T. & Anderson, R. G. (1998) J. Biol. Chem. 273, 21099–21104
35. Parton, R. G. & Hancock, J. F. (2001) Methods Enzymol. 333, 172–183
36. Pol, A., Calvo, M., Lu, A. & Enrich, C. (1999) Hepatology 29, 1848–1857
37. Pol, A., Luetterforst, R., Lindsay, M., Heino, S., Ikonen, E. & Parton, R. G.
(2001) J. Cell Biol. 152, 1057–1070
38. Kolch, W. (2000) Biochem. J. 351, 289–305
39. Cowley, S., Paterson, H., Kemp, P. & Marshall, C. J. (1994) Cell 77, 841–852
40. Galbiati, F., Volonte, D., Minetti, C., Chu, J. B. & Lisanti, M. P. (1999) J. Biol.
Chem. 274, 25632–25641
41. Esteban, L. M., Vicario-Abejon, C., Fernandez-Salguero, P., Fernandez-
Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M.,
McKay, R., Ward, J. M., Pellicer, A. & Santos, E. (2001) Mol. Cell. Biol. 21,
1444–1452
42. Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt,
E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R. & Jacks,
T. (1997) Genes Dev. 11, 2468–2481
43. Henderson, L. P., Lin, L., Prasad, A., Paul, C. A., Chang, T. Y. & Maue, R. A.
(2000) J. Biol. Chem. 275, 20179–20187
44. de Paula, F., Vainzof, M., Bernardino, A. L., McNally, E., Kunkel, L. M. & Zatz,
M. (2001) Am. J. Med. Genet. 99, 303–307
Caveolin-3 Mutants and Lipid Raft-dependent Signaling 17949









Clyde-Smith, Ian A. Prior, Susan J. Nixon, John F. Hancock and Robert G. Parton
Amanda J. Carozzi, Sandrine Roy, Isabel C. Morrow, Albert Pol, Bruce Wyse, Jodi
Caveolin-3
Inhibition of Lipid Raft-dependent Signaling by a Dystrophy-associated Mutant of
doi: 10.1074/jbc.M110879200 originally published online March 7, 2002
2002, 277:17944-17949.J. Biol. Chem. 
  
 10.1074/jbc.M110879200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/277/20/17944.full.html#ref-list-1
This article cites 44 references, 28 of which can be accessed free at
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
